Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors
June 09 2014 - 8:30AM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular
diseases, today announced that Robert E. Conway, has been elected
Chairman of the Company’s Board of Directors. He serves on the
Audit and Compensation Committees of the Board of Directors.
Mr. Conway has over 30 years of executive leadership experience
in the pharmaceutical and biotechnology industries. Mr. Conway
served as the Chief Executive Officer and member of the Board of
Directors of Array BioPharma from 1999 to 2012. Array is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer and inflammatory diseases. Prior to
joining Array, Mr. Conway was the Chief Operating Officer and
Executive Vice President of Hill Top Research, Inc., a clinical
research services company, from 1996 to 1999. He also held various
executive positions for Corning Inc. including Corporate Vice
President and General Manager of Corning Hazleton, Inc., a contract
research organization. Mr. Conway serves as the Chairman of Wall
Family Enterprise, a leading library and education supplies
company. He is on the Board of Directors of eResearch Technology,
Inc. In addition, Mr. Conway is a member of the Strategic Advisory
Committee of Genstar Capital, LLC.
“Bob’s experience and leadership are a tremendous asset to
ARCA,” said Dr. Michael R. Bristow, President and Chief Executive
Officer of ARCA. “With his significant experience in leading both
drug development efforts and companies in the biopharmaceutical
sector, Bob’s input and guidance be valuable to the ARCA Board as
we continue the development of Gencaro and look to deliver value to
our stockholders.”
“I am honored to accept this role with the ARCA Board of
Directors,” said Mr. Conway. “This is an exciting time for the
organization with the GENETIC-AF trial under way. We believe there
is an unmet medical need for new atrial fibrillation treatments.
The GENETIC-AF trial, conducted with the collaboration of
Medtronic, will hopefully provide important new data for the atrial
fibrillation community.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases. The Company's lead product
candidate, GencaroTM (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for atrial fibrillation. ARCA has
identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to
be the first genetically-targeted atrial fibrillation prevention
treatment. ARCA has a collaboration with Medtronic, Inc. for
support of the GENETIC-AF trial. For more information please visit
www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, but are
not limited to, statements regarding, potential timing for patient
enrollment in the GENETIC-AF trial, the sufficiency of the
Company’s capital to support its operations, the potential for
genetic variations to predict individual patient response to
Gencaro, Gencaro’s potential to treat atrial fibrillation, future
treatment options for patients with atrial fibrillation, and the
potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company's financial
resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the
protection and market exclusivity provided by the Company’s
intellectual property; risks related to the drug discovery and the
regulatory approval process; and, the impact of competitive
products and technological changes. These and other factors are
identified and described in more detail in ARCA’s filings with the
SEC, including without limitation the Company’s annual report on
Form 10-K for the year ended December 31, 2013, and subsequent
filings. The Company disclaims any intent or obligation to update
these forward-looking statements.
ARCA biopharma, Inc.Investor & Media Contact:Derek
Cole, 720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024